Who is affected by this change?

This affects Independence Blue Cross Endocrinology, Pediatrics, Neurology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective May 28, 2025.

Back to dashboard

Medicare AdvantageCoverageLow impact

MA08.147, Velmanase alfa (Lamzede)

Independence Blue Cross·Endocrinology, Pediatrics, Neurology·Medical Policy

Effective date

May 28, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.147 for Velmanase alfa (Lamzede) has been reissued and will become effective May 28, 2025. This appears to be an updated policy for this rare enzyme replacement therapy used to treat alpha-mannosidosis.

Action Required

Action needed

By May 28, 2025: Billing team should review the complete updated policy MA08.147 for Velmanase alfa (Lamzede) on the IBX website to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for this rare enzyme replacement therapy.

Related policy hubs

Independence Blue Cross policies Endocrinology Pediatrics Neurology